The Triple Threat
Next-gen weight loss meets targeted fat metabolism.
$428/mo
$359/mo
Save $69/mo vs. buying individually
2 protocols included
How This Stack Works
Retatrutide activates three incretin/metabolic receptors: GLP-1 (appetite suppression via hypothalamic signaling), GIP (enhanced insulin sensitivity and fat metabolism), and glucagon (increased hepatic fat oxidation and energy expenditure). AOD-9604 (HGH fragment 177-191) binds fat cell receptors to activate hormone-sensitive lipase, breaking down triglycerides directly. The combination addresses intake, expenditure, and stored fat simultaneously.
Why This Combination
This is the most aggressive weight management stack we offer. Retatrutide is the first triple agonist — activating GLP-1 (appetite), GIP (insulin sensitivity), and glucagon (energy expenditure and fat oxidation) receptors simultaneously. Clinical trials show it outperforms every dual or single agonist on the market. AOD-9604 adds a complementary mechanism: it's a fragment of growth hormone that acts directly on fat cell receptors, stimulating lipolysis without any effect on blood sugar or organ growth. Together, you get reduced appetite, increased energy expenditure, improved metabolic health, and direct fat cell targeting.
Ideal For
Maximum weight loss goals
Those who want the newest available science
Stubborn fat that resists other approaches
Comprehensive metabolic transformation
What to Expect
Week 1–2
Initiation
Appetite begins declining. Energy expenditure increases from glucagon activation.
Week 3–4
Titration
Retatrutide dose increases. All three receptor pathways are now active. Fat metabolism accelerates.
Week 6–8
Acceleration
Significant weight loss. Stubborn fat deposits begin responding to AOD-9604.
Week 12+
Maximum Effect
Full triple-agonist plus fat-targeting efficacy. Body composition transformation.
Ready to start?
The Triple Threat — $359/mo. Save $69 vs. buying separately. Care team reviewed. Ships free.
HSA/FSA eligible · Cancel anytime · Ships in 3-5 days